A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

@article{Coleman2012API,
  title={A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.},
  author={Robert L. Coleman and Michael W. Sill and Heather A. Lankes and Amanda N Fader and Neil J. Finkler and James S. Hoffman and Peter G Rose and Gregory P. Sutton and Charles W. Drescher and Donald Scott McMeekin and Wei Hu and Michael T. Deavers and Andrew K. Godwin and R Katherine Alpaugh and Anil Sood},
  journal={Gynecologic oncology},
  year={2012},
  volume={127 3},
  pages={538-43}
}
OBJECTIVES Aflibercept targets vascular endothelial growth factor and placental growth factor. We evaluated activity and toxicity of aflibercept in recurrent/persistent endometrial cancer patients. Biomarkers and association with clinical characteristics and outcome were explored. METHODS Eligible patients had measurable disease; 1-2 prior cytotoxic regimens; performance status 0-2. Aflibercept 4 mg/kg IV q14 days (28-day cycles) was administered until disease progression or prohibitive… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
23 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…